Loading
A phase 3 trial of leucovorin (folinic acid), panitumumab, bevacizumab (glioblastoma use) and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Federation Francophone de Cancerologie Digestive, now recruiting.
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver is a phase 3, randomised interventional study registered as NCT02885753 by Federation Francophone de Cancerologie Digestive, with a registry enrolment figure of 348 participants, started 2016-12 and due to reach its primary completion in 2028-09. Interventions recorded: Oxaliplatin intravenous; 5 FU bolus; Folinic acid; Oxaliplatin intra-arteriel; Panitumumab; Bevacizumab; 5 FU continuous; Irinotecan. Conditions listed: Colorectal Neoplasms. Primary outcome: progression-free survival. Colorectal eligibility wording from the registry: "* Histologically proven colorectal adenocarcinoma with hepatic metastasis(es)". Sites: Belgium, France. No results are recorded here; the registry entry is the source.
Shares Panitumumab, FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Panitumumab, FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Leucovorin (folinic acid), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.